Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) were down 1.3% during trading on Wednesday . The company traded as low as $213.75 and last traded at $214.72. Approximately 5,581,613 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 7,351,497 shares. The stock had previously closed at $217.49.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Potential tax windfall — analyses say recent federal tax changes pushed corporate cash tax bills materially lower, which could improve AbbVie’s cash flow and net cash taxes versus prior expectations. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
- Positive Sentiment: Allergan Aesthetics consumer push — AbbVie’s Allergan Aesthetics rolled out its CoolMonth promotion, a recurring revenue and demand driver in the aesthetics business (incremental, but recurring). Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth
- Positive Sentiment: Near-term buying interest — recent market coverage flagged a modest uptick in AbbVie shares amid broader market moves, suggesting some investor buying despite underperformance vs. the market. AbbVie Inc. stock rises Tuesday, still underperforms market
- Neutral Sentiment: Upcoming earnings catalyst — AbbVie will report Q1 2026 results on April 29; investors will focus on guidance, Imbruvica pricing/volume, and contributions from newer oncology drugs. AbbVie to Host First-Quarter 2026 Earnings Conference Call
- Neutral Sentiment: Industry read — a new PatentVest report highlights heavy investment in obesity (amylin) programs; broader shifts in pharma priorities and deal activity could indirectly affect AbbVie’s M&A and pipeline strategy. PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race
- Negative Sentiment: Litigation tied to Cerevel deal — a Bloomberg Law ruling forces Pfizer and Bain to litigate a suit by Cerevel investors over AbbVie’s deal, adding legal uncertainty and potential transaction risk/drag on the acquisition timeline. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
- Negative Sentiment: Oncology headwinds — analyst commentary flags pricing pressure on Imbruvica and a possible 2026 sales dip despite new oncology launches, which could weigh on top‑line growth expectations. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
- Negative Sentiment: Competitive pressure — recent large oncology M&A (e.g., Merck’s deal) strengthens rivals’ pipelines and could intensify competition in key oncology markets. Merck Just Made a Big Bet on a New Cancer Growth Engine
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on ABBV. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.
AbbVie Price Performance
The company’s 50-day moving average price is $222.00 and its two-hundred day moving average price is $224.65. The company has a market capitalization of $379.66 billion, a P/E ratio of 90.98, a price-to-earnings-growth ratio of 0.74 and a beta of 0.34.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.
Insider Buying and Selling at AbbVie
In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.
Institutional Trading of AbbVie
Several hedge funds and other institutional investors have recently bought and sold shares of ABBV. Norges Bank bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP raised its holdings in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Capital World Investors lifted its position in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after acquiring an additional 6,736,161 shares during the period. Cardano Risk Management B.V. lifted its position in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
